EcoDrugPlus

Dihydropyrimidine Dehydrogenase A, Tandem Duplicate 1

Ensembl ID : ENSDARG00000086853
Gene Symbol: DPYDA.1
5 Cross references
169 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSDARG00000010267
Gene Symbol: DPYDB
4 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2a

Ensembl ID : ENSDARG00000100693
Gene Symbol: DDR2A
2 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2b

Ensembl ID : ENSDARG00000058695
Gene Symbol: DDR2B
5 Cross references
190 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSDARG00000038918
Gene Symbol: DRD1B
8 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSDARG00000056926
Gene Symbol: DRD2A
5 Cross references
204 Possible Orthologues:

Dopamine Receptor D2b

Ensembl ID : ENSDARG00000011091
Gene Symbol: DRD2B
6 Enzyme and pathways 5 Cross references
145 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSDARG00000032131
Gene Symbol: DRD3
10 Enzyme and pathways 5 Cross references
203 Possible Orthologues:

Dopamine Receptor D4a

Ensembl ID : ENSDARG00000038363
Gene Symbol: DRD4A
5 Cross references
176 Possible Orthologues:

Dopamine Receptor D4b

Ensembl ID : ENSDARG00000035820
Gene Symbol: DRD4B
8 Enzyme and pathways 5 Cross references
176 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSDARG00000037576
Gene Symbol: DRD5
8 Enzyme and pathways 6 Cross references
158 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 1a

Ensembl ID : ENSDARG00000038996
Gene Symbol: EGLN1A
5 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).